Acorda Therapeutics Inc
OTC:ACORQ
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Acorda Therapeutics Inc
OTC:ACORQ
|
20k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.8B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Acorda Therapeutics Inc
Glance View
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Ardsley, New York and currently employs 118 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Acorda Therapeutics Inc is -236.1%, which is below its 3-year median of -44.1%.
Over the last 3 years, Acorda Therapeutics Inc’s Operating Margin has decreased from -26.5% to -236.1%. During this period, it reached a low of -236.1% on May 1, 2024 and a high of 8.8% on Sep 30, 2023.
